Terminal Ileitis

Disclaimer: This information is intended for educational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Clinical decisions must always be made by a qualified healthcare professional, taking into account the individual patient's condition and current best evidence.

Overview

• Definition: Terminal ileitis refers to inflammation specifically affecting the terminal ileum, the final segment of the small intestine before it joins the large intestine. It is a descriptive diagnosis rather than a definitive disease and can result from a variety of etiologies, both acute and chronic. The most common chronic cause is Crohn's disease.
• Epidemiology: The epidemiology of terminal ileitis largely reflects its underlying causes.
  • Crohn's Disease (CD): The incidence of CD is estimated at 3-20 cases per 100,000 person-years, with prevalence rates ranging from 20-400 per 100,000 population, varying geographically. The ileocolonic region, including the terminal ileum, is affected in approximately 50% of CD patients.
  • Infectious Ileitis: Incidence varies widely based on pathogen, geography, season, and sanitation. Common causes like Yersinia enterocolitica or Campylobacter are more prevalent in certain regions or during outbreaks. Mycobacterium tuberculosis ileitis is endemic in many parts of the world.
  • NSAID-Induced Enteropathy: Common in chronic NSAID users, with up to 70% of regular users showing some degree of small bowel mucosal injury, although clinically symptomatic terminal ileitis is less frequent.
• Classification: Terminal ileitis can be broadly classified by its duration and etiology:
  • Acute Terminal Ileitis: Often self-limiting, commonly infectious (e.g., Yersinia, Campylobacter, Salmonella, Shigella, E. coli, Clostridioides difficile, viral, parasitic), or drug-induced (e.g., NSAIDs). Can also be seen in acute appendicitis, diverticulitis of the ileum, or ischemia.
  • Chronic Terminal Ileitis: Persistent or recurrent inflammation, most commonly associated with Crohn's disease. Other chronic causes include intestinal tuberculosis, lymphoma, radiation enteritis, Behcet's disease, and chronic ischemia.
  • Specific Etiologies:
    • Inflammatory Bowel Disease (IBD): Crohn's disease (most common).
    • Infectious: Yersinia enterocolitica, Campylobacter jejuni, Salmonella spp., Mycobacterium tuberculosis, Escherichia coli (e.g., enteroinvasive), C. difficile, Cytomegalovirus (CMV), parasites (e.g., Anisakis), fungi.
    • Drug-induced: NSAIDs, mycophenolate mofetil.
    • Ischemic: Mesenteric ischemia.
    • Neoplastic: Lymphoma, carcinoid tumor, adenocarcinoma.
    • Other: Radiation enteritis, vasculitis, eosinophilic enteritis, diverticulitis of the ileum, appendicitis with contiguous inflammation.

Pathophysiology

• Mechanism: The underlying mechanisms vary significantly with the etiology:
  • Crohn's Disease: Involves a complex interplay of genetic predisposition, dysregulated immune responses, environmental factors, and an altered gut microbiome. Characterized by transmural inflammation, skip lesions, granulomas (non-caseating), and eventual fibrosis, strictures, fistulae, and abscesses. The terminal ileum is particularly susceptible due to its rich lymphoid tissue (Peyer's patches) and high bacterial load.
  • Infectious Ileitis: Pathogens directly invade the intestinal mucosa (e.g., Yersinia, Salmonella), produce toxins, or trigger an immune response. This leads to inflammation, mucosal ulceration, and often mesenteric lymphadenitis. Some, like Yersinia, can mimic Crohn's disease with granuloma formation.
  • NSAID-Induced Enteropathy: NSAIDs inhibit cyclooxygenase-1 (COX-1) and COX-2 enzymes, leading to reduced prostaglandin synthesis. Prostaglandins are crucial for maintaining mucosal integrity and blood flow. This causes increased intestinal permeability, direct mucosal damage, and secondary inflammation.
  • Ischemic Ileitis: Reduced blood flow to the terminal ileum, often due to atherosclerosis, emboli, or hypoperfusion, leading to hypoxia, mucosal injury, and inflammation.
  • Tuberculosis: Ingestion of M. tuberculosis bacilli, typically affecting the ileocecal region due to physiological stasis and abundant lymphoid tissue. Causes granulomatous inflammation, ulceration, strictures, and sometimes perforation or fistula.
  • Lymphoma: Infiltration of the ileal wall by malignant lymphocytes, leading to thickening, ulceration, and potentially obstruction or bleeding.
• Risk Factors:
  • Crohn's Disease: Family history of IBD, smoking (strongest modifiable risk factor), appendectomy (controversial), Western diet (high fat, sugar, processed foods), urban living, certain medications (e.g., NSAIDs, oral contraceptives, antibiotics) may trigger flares.
  • Infectious Ileitis: Consumption of contaminated food or water, travel to endemic areas, immunosuppression (e.g., HIV, transplant recipients, chemotherapy), young age, close contact with infected individuals/animals.
  • NSAID-Induced Enteropathy: Chronic NSAID use, higher NSAID doses, concomitant corticosteroid use, age >65 years, history of peptic ulcer disease.
  • Ischemic Ileitis: Atherosclerosis, advanced age, hypercoagulable states, cardiac arrhythmias, low cardiac output states, cocaine use.
  • Tuberculosis: Immigration from endemic areas, immunosuppression (HIV, biologics), close contact with active TB cases, poverty, overcrowding.
• Protective Factors:
  • Crohn's Disease: Breastfeeding, smoking cessation, potentially a diet rich in fruits/vegetables and fiber (though evidence is not definitive for prevention).
  • Infectious Ileitis: Good hygiene practices, safe food and water preparation, proper vaccination (where available).
  • NSAID-Induced Enteropathy: Judicious use of NSAIDs, concurrent use of proton pump inhibitors (PPIs) for gastric protection (less effective for small bowel), alternative pain management strategies.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Right Lower Quadrant (RLQ) Abdominal Pain: Often cramping or colicky, can be constant, exacerbated by eating (food avoidance).
  • Diarrhea: Can be watery or mucoid, with or without blood (more common in colonic involvement, but can occur in severe ileitis).
  • Weight Loss: Common due to malabsorption (bile salts, B12), reduced oral intake (pain, fear of eating), and systemic inflammation.
  • Fever: Especially with infectious causes, active inflammation, or abscess formation.
  • Nausea and Vomiting: More prominent with partial obstruction or severe inflammation.
• Early Signs:
  • Intermittent RLQ pain.
  • Mild changes in bowel habits (e.g., increased frequency or softer stools).
  • Fatigue.
  • Low-grade fever.
  • Anorexia.
• Advanced Signs:
  • Obstructive Symptoms: Severe cramping pain, abdominal distension, obstipation, vomiting (due to stricture formation from chronic inflammation and fibrosis).
  • Fistula Symptoms: Enterocutaneous (peristomal drainage), enteroenteric (changes in bowel habits, malabsorption, nutrient deficiencies), enterovesical (recurrent UTIs, pneumaturia, fecaluria), perianal (abscesses, skin tags, fissures).
  • Abscess Formation: Localized RLQ pain, tender mass, spiking fevers, chills, leukocytosis.
  • Perforation: Sudden, severe abdominal pain, signs of peritonitis, fever, hemodynamic instability (medical emergency).
  • Malnutrition and Deficiencies: Anemia (iron, B12 deficiency), hypoproteinemia, vitamin D deficiency, osteopenia/osteoporosis.
  • Extra-intestinal Manifestations (EIMs) (Crohn's): Arthralgias/arthritis (peripheral and axial), erythema nodosum, pyoderma gangrenosum, uveitis, episcleritis, primary sclerosing cholangitis (rare with isolated ileitis).
• Atypical Presentations:
  • Mimicking acute appendicitis (especially with Yersinia or acute CD flares).
  • Isolated perianal disease without significant bowel symptoms in CD.
  • Unexplained iron deficiency anemia or B12 deficiency.
  • Prolonged fever of unknown origin.
  • Presenting with solely extra-intestinal manifestations.

Physical Examination

• Inspection:
  • General: Signs of weight loss, pallor (anemia), signs of dehydration.
  • Abdomen: Distension (obstruction), scars from previous surgeries, fistulae openings (enterocutaneous).
  • Skin: Erythema nodosum (tender red nodules on shins), pyoderma gangrenosum (painful necrotic ulcers), skin tags, fissures, abscesses around the perianal area (CD).
  • Eyes: Iritis, conjunctivitis.
  • Joints: Swelling, tenderness (arthritis).
• Palpation:
  • Right Lower Quadrant Tenderness: Common, localized.
  • RLQ Mass: May indicate an inflamed loop of ileum, phlegmon, or abscess.
  • Rebound Tenderness/Guarding: Suggests peritoneal irritation, possibly due to perforation or severe inflammation/abscess.
  • Psoas Sign: Positive if pain elicited by passive hip extension or active hip flexion against resistance, suggestive of inflammation involving the psoas muscle (e.g., retroperitoneal abscess).
• Special Tests:
  • Perianal examination (if CD suspected): Look for skin tags, fissures, fistulae, abscesses.
  • Rectal examination: May reveal tenderness, masses, or perianal pathology.

Diagnostic Approach

History Taking

• Key Questions:
  • Pain Characteristics: Location (RLQ), onset (acute vs. gradual), duration, frequency, character (cramping, sharp), radiation, severity (0-10 scale), aggravating/alleviating factors (e.g., food, defecation).
  • Bowel Habits: Frequency, consistency (Bristol stool chart), presence of blood, mucus, pus, urgency, tenesmus.
  • Constitutional Symptoms: Fever, chills, night sweats, weight loss (quantify), anorexia, fatigue.
  • Past Medical History: Previous GI issues, appendectomy, IBD family history, autoimmune diseases, TB exposure, recent infections, foreign travel.
  • Medications: Current and recent use of NSAIDs, antibiotics, immunosuppressants.
  • Social History: Smoking status (critical for CD), alcohol use, illicit drug use.
  • Dietary History: Recent food intake, food intolerances.
  • Extra-intestinal Symptoms: Joint pain, skin rashes, eye irritation.
• Red Flags:
  • Severe, sudden onset abdominal pain (perforation, severe ischemia).
  • Signs of peritonitis (guarding, rigidity, rebound tenderness).
  • Signs of intestinal obstruction (abdominal distension, obstipation, bilious vomiting).
  • Significant GI bleeding (hematochezia, melena, or hemodynamic instability).
  • High fever with chills and signs of sepsis.
  • Rapidly worsening symptoms or signs of systemic toxicity.
  • Unexplained significant weight loss.

Laboratory Tests

• First-Line:
  • Complete Blood Count (CBC): Anemia (chronic disease, iron/B12 deficiency), leukocytosis (inflammation, infection, abscess).
  • Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP): Non-specific markers of inflammation; elevated in active ileitis.
  • Comprehensive Metabolic Panel (CMP): Electrolytes, renal function, liver function, albumin (low in malnutrition).
  • Stool Studies:
    • Stool Culture with Sensitivity: For common bacterial pathogens (Salmonella, Shigella, Campylobacter, Yersinia, E. coli).
    • Ova and Parasites (O&P): For parasitic infections (e.g., Giardia, Entamoeba).
    • Clostridioides difficile Toxin/PCR: If recent antibiotic use or hospital exposure.
  • Fecal Calprotectin: A sensitive and specific marker for intestinal inflammation, useful for screening for IBD and monitoring disease activity. Values >250 µg/g strongly suggest intestinal inflammation.
• Confirmatory:
  • Specific Serologies (for Crohn's): Anti-Saccharomyces cerevisiae antibodies (ASCA) and atypical perinuclear antineutrophil cytoplasmic antibodies (pANCA). ASCA is more specific for CD, pANCA more for ulcerative colitis, but their role is primarily supportive and not diagnostic of CD in isolation.
  • Tuberculosis Workup:
    • Interferon-Gamma Release Assay (IGRA) (e.g., QuantiFERON-TB Gold, T-SPOT.TB) or Purified Protein Derivative (PPD) skin test: For latent TB infection, which can reactivate.
    • Acid-Fast Bacilli (AFB) Smear and Culture: From stool, tissue biopsy, or other body fluids if TB is suspected.
  • Cytomegalovirus (CMV) PCR: In immunocompromised patients with suspected CMV ileitis.
  • Vitamin B12 levels: To assess for terminal ileum malabsorption.
  • Iron Studies: For iron deficiency anemia.
• Monitoring:
  • Repeat ESR/CRP and Fecal Calprotectin: To assess response to treatment and monitor disease activity.
  • CBC, CMP: For nutritional status and medication side effects.
  • Therapeutic Drug Monitoring (TDM): For biologics (e.g., anti-TNF agents) to optimize dosing and detect antibodies to the drug.

Imaging

• Recommended:
  • Cross-Sectional Enterography (CT Enterography or MR Enterography):
    • CT Enterography (CTE): High spatial resolution, rapid acquisition. Preferred for acute settings to rule out complications like abscess or obstruction. Findings include bowel wall thickening (>3-4 mm), mucosal hyperenhancement, engorged vasa recta (comb sign), fat stranding, strictures, fistulas, abscesses. Sensitivity >90%, specificity >90% for active Crohn's.
    • MR Enterography (MRE): No ionizing radiation, excellent soft tissue contrast, superior for detecting inflammation, fistulae, and mural edema. Preferred for young patients, pregnant women, and long-term monitoring. Findings similar to CTE, often better for subtle inflammation and intramural/transmural changes.
  • Colonoscopy with Ileoscopy and Biopsies: Essential for direct visualization of the terminal ileum and obtaining tissue for histopathological examination.
    • Findings in CD: Aphthous ulcers, linear ulcers, cobblestoning, strictures, skip lesions, pseudopolyps. Biopsies reveal transmural inflammation, crypt architectural distortion, focal acute inflammation, and non-caseating granulomas (in 30-60% of cases).
    • Findings in Infectious Ileitis: Diffuse or focal inflammation, erosions, ulcers; specific changes may suggest particular pathogens (e.g., deep linear ulcers in CMV, pseudomembranes in C. difficile).
    • Findings in TB: Transverse ulcers, nodularity, strictures, distortion of ileocecal valve, biopsies may show caseating granulomas.
  • Abdominal Ultrasound (US): Useful initial screening, especially in children and pregnant women, or for serial monitoring. Can detect bowel wall thickening, mural hyperemia (Doppler), fluid collections, and dilated loops proximal to obstruction. Limited by operator dependency and body habitus.
• Advanced:
  • Capsule Endoscopy: Excellent for visualizing the entire small bowel mucosa and detecting subtle lesions (e.g., aphthous ulcers in early CD). Contraindicated in known or suspected strictures due to risk of retention/obstruction. Should only be performed after cross-sectional imaging has ruled out significant strictures.
  • Double-Balloon or Single-Balloon Enteroscopy: Allows for therapeutic interventions (e.g., stricture dilation, biopsy beyond standard reach) and detailed visualization of the small bowel. Often used after capsule endoscopy identifies a lesion or if intervention is needed.

Management

Acute Management

• Immediate:
  • NPO (Nil per os): To rest the bowel, especially if obstruction or severe inflammation is suspected.
  • Intravenous Fluids: To correct dehydration and electrolyte imbalances, particularly with severe diarrhea or vomiting.
  • Pain Control: Opioids (e.g., morphine 2-4 mg IV PRN) or non-opioid analgesics (e.g., acetaminophen 1000 mg PO/IV, ketorolac 15-30 mg IV/IM) depending on severity and etiology. Avoid NSAIDs if NSAID-induced enteropathy is suspected or in active IBD with ulceration.
• Stabilization:
  • Empiric Antibiotics: If infectious etiology is strongly suspected or to cover for bacterial translocation in severe inflammation/abscess. Broad-spectrum antibiotics (e.g., ciprofloxacin 500 mg PO BID or metronidazole 500 mg PO/IV TID, or combination) may be used while awaiting stool culture results.
  • Nutritional Support: Consider total parenteral nutrition (TPN) for severe cases with significant weight loss, obstruction, or inability to tolerate oral intake, until enteral feeding is possible.
  • Corticosteroids: For acute flares of Crohn's disease (e.g., methylprednisolone 40-60 mg IV daily or prednisone 40-60 mg PO daily) to rapidly reduce inflammation. Tapering usually initiated once symptoms improve.
• Emergency:
  • Surgical Consultation: Required for complications such as intestinal obstruction not responding to medical management, perforation, intra-abdominal abscess (especially if not amenable to percutaneous drainage), uncontrolled hemorrhage, or toxic megacolon (rare in isolated ileitis).
  • Abscess Drainage: Percutaneous image-guided drainage should be attempted for most intra-abdominal abscesses. Surgical drainage is indicated if percutaneous drainage fails or is not feasible.

Chronic Management

Management is highly dependent on the underlying cause.

Crohn's Disease

• Pharmacological:
  • Induction of Remission (Moderate-to-Severe):
    • Corticosteroids: Prednisone 40-60 mg PO daily or budesonide (9 mg PO daily, less systemic side effects) for 8-16 weeks. Budesonide is specifically effective for ileal CD. Taper off once symptoms improve.
    • Anti-TNF Agents: Infliximab (5 mg/kg IV at weeks 0, 2, 6, then every 8 weeks), Adalimumab (160/80 mg SC induction, then 40 mg SC every other week), Certolizumab pegol.
    • Anti-Integrins: Vedolizumab (300 mg IV at weeks 0, 2, 6, then every 8 weeks), Ustekinumab (initial IV dose based on weight, then 90 mg SC every 8-12 weeks).
    • JAK Inhibitors: Upadacitinib (45 mg PO daily for 12 weeks, then 15-30 mg PO daily) for moderate-to-severe CD.
  • Maintenance of Remission:
    • Immunomodulators: Azathioprine (2-2.5 mg/kg/day PO) or 6-mercaptopurine (1-1.5 mg/kg/day PO). Requires TPMT enzyme testing before initiation and regular CBC monitoring. Methotrexate (15-25 mg IM/SC weekly) is an alternative.
    • Biologics: Continue anti-TNF, anti-integrin, or anti-IL12/23 agents as per induction regimen.
    • Small Molecules: Continue JAK inhibitors.
    • Aminosalicylates (5-ASA, e.g., Mesalamine): Less effective for moderate-to-severe ileal CD, mainly used for mild colonic CD or as an adjunct.
• Non-pharmacological:
  • Nutritional Support: Oral supplementation, elemental/polymeric diets, or TPN for severe malnutrition or during active flares.
  • Diet Modification: Low-residue diet during flares or strictures. FODMAP diet may help with symptomatic relief but does not treat inflammation.
  • Smoking Cessation: Critical for reducing disease activity, recurrence, and need for surgery in CD.
  • Psychological Support: Stress management, counseling, support groups.
• Monitoring: Regular clinical assessment, endoscopic evaluation (ileocolonoscopy) every 1-2 years to assess mucosal healing, Fecal Calprotectin, ESR/CRP, CBC, CMP, and vitamin levels (B12, D, iron). For biologics, therapeutic drug monitoring (trough levels and anti-drug antibodies).

Infectious Ileitis

• Pharmacological:
  • Yersinia: Usually self-limiting. Antibiotics (e.g., ciprofloxacin 500 mg PO BID or doxycycline 100 mg PO BID) for severe cases, immunocompromised patients, or bacteremia, typically for 7-14 days.
  • Campylobacter: Usually self-limiting. Azithromycin (500 mg PO daily for 3 days) for severe cases or immunocompromised patients.
  • Salmonella: Usually self-limiting. Antibiotics (e.g., ciprofloxacin, azithromycin) for severe disease, immunocompromised, or risk of systemic infection.
  • Tuberculosis: Multi-drug anti-tubercular therapy (ATT) typically for 6-12 months (e.g., rifampicin, isoniazid, pyrazinamide, ethambutol for initial 2 months, then rifampicin and isoniazid for 4-10 months). Directly observed therapy (DOT) is recommended.
  • C. difficile: Oral vancomycin (125 mg PO QID for 10-14 days) or fidaxomicin (200 mg PO BID for 10 days).
  • CMV: Ganciclovir (5 mg/kg IV BID for 14-21 days, then oral valganciclovir) in immunocompromised patients.
• Non-pharmacological: Hydration, supportive care.
• Monitoring: Resolution of symptoms, repeat stool cultures if indicated, follow-up imaging for TB resolution.

NSAID-Induced Ileitis

• Pharmacological: Discontinuation of NSAID is paramount. Proton pump inhibitors (PPIs) (e.g., omeprazole 20-40 mg PO daily) may aid healing, although primary benefit is often gastric.
• Non-pharmacological: Use alternative pain management strategies.
• Monitoring: Symptom resolution, potentially repeat imaging or endoscopy if symptoms persist.

Treatment Algorithms

• First-Line (General):
  • Rule out acute surgical emergencies (perforation, complete obstruction).
  • Assess for infection: Stool cultures, C. difficile testing. Treat specific pathogens with appropriate antibiotics/antivirals/antiparasitics.
  • Consider NSAID-induced: Discontinue NSAID.
  • Acute Crohn's Flare: Oral corticosteroids (budesonide for mild-moderate ileal CD, prednisone for moderate-to-severe) for induction, then transition to maintenance.
• Second-Line (Crohn's Disease):
  • If corticosteroids fail or are contraindicated, or if the disease is moderate-to-severe, consider biologic therapy (anti-TNF, anti-integrin, anti-IL12/23) or JAK inhibitors.
  • Concomitant use of immunomodulators (azathioprine, 6-MP, methotrexate) for maintenance or in combination with biologics.
• Refractory Cases (Crohn's Disease):
  • Optimize Biologic Therapy: Therapeutic drug monitoring, dose escalation, or switching to a different class of biologic.
  • Combination Therapy: Biologic + immunomodulator.
  • Surgery: Indicated for medically refractory disease, strictures causing obstruction, recurrent fistulas or abscesses, perforation, or severe bleeding. Resection of the inflamed terminal ileum is a common procedure, but recurrence rates are high.
  • Clinical Trials: Enrollment in trials for novel agents.

Complications

• Common:
  • Abdominal Abscess: Due to transmural inflammation leading to bacterial translocation and localized infection.
  • Strictures: Narrowing of the bowel lumen due to chronic inflammation and fibrosis, leading to partial or complete bowel obstruction.
  • Fistulas: Abnormal connections between the inflamed bowel segment and other organs (e.g., other bowel loops, bladder, vagina, skin).
  • Malnutrition and Nutritional Deficiencies: Due to malabsorption (especially B12, fat-soluble vitamins, iron) and reduced oral intake.
  • Anemia: Iron deficiency (blood loss, malabsorption) or B12 deficiency (terminal ileum involvement).
• Serious:
  • Intestinal Obstruction: Complete blockage requiring surgical intervention.
  • Perforation: A hole in the bowel wall, leading to peritonitis and sepsis, a surgical emergency.
  • Toxic Megacolon: Rare in isolated ileitis, but can occur with severe fulminant colitis if inflammation extends.
  • Sepsis: From untreated abscess, perforation, or severe infection.
  • Increased Risk of Colorectal Cancer: With longstanding Crohn's disease, particularly with colonic involvement, but also with ileal disease (surveillance colonoscopy recommended).
• Long-term:
  • Recurrent disease activity (Crohn's).
  • Need for repeated surgeries (Crohn's).
  • Chronic pain.
  • Osteoporosis/osteopenia (due to chronic inflammation, corticosteroid use, vitamin D deficiency).
  • Increased risk of thromboembolic events (due to chronic inflammation).
  • Renal stones and gallstones (especially with ileal resection in Crohn's).

Prognosis

• Factors:
  • Etiology: Prognosis for most infectious causes is excellent with full recovery. Crohn's disease is a chronic, relapsing-remitting condition.
  • Disease Severity at Diagnosis: More severe inflammation, presence of complications (strictures, fistulas) indicate a more aggressive course in CD.
  • Response to Treatment: Early and sustained response to medical therapy (mucosal healing) is associated with a better prognosis in CD.
  • Smoking Status: Smokers with CD have a more aggressive disease course, higher rates of relapse, and increased need for surgery.
  • Presence of Extra-intestinal Manifestations: May indicate more systemic inflammation.
• Survival:
  • Infectious Ileitis: Generally excellent, with full recovery expected. Fatalities are rare, usually occurring in immunocompromised individuals or from severe complications like perforation.
  • Crohn's Disease: While CD is not typically a direct cause of death, it is associated with increased morbidity and a slightly reduced life expectancy (a few years) compared to the general population, primarily due to complications and treatment-related issues.
• Quality of Life:
  • Can be significantly impaired, especially in chronic conditions like Crohn's disease, due to chronic pain, diarrhea, fatigue, fear of flares, surgical interventions, and the impact of extra-intestinal manifestations.
  • Effective disease management, including medical, surgical, nutritional, and psychological support, aims to improve quality of life.

Prevention

• Primary:
  • Infectious Ileitis: Practice good hand hygiene, ensure safe food and water consumption (e.g., cook meat thoroughly, avoid unpasteurized dairy), prudent travel precautions in endemic areas.
  • NSAID-Induced Ileitis: Limit unnecessary NSAID use, use the lowest effective dose for the shortest duration, consider alternative pain relief.
  • Crohn's Disease: No proven primary prevention strategies exist. Research is ongoing into dietary factors, early life exposures, and microbiome modulation. Smoking cessation is crucial for those at risk or with established disease.
• Secondary:
  • Early Detection and Intervention: Prompt diagnosis and initiation of appropriate therapy for Crohn's disease aim to prevent progression, complications (strictures, fistulae), and the need for surgery. Regular monitoring (clinical, biochemical, endoscopic) is key.
  • Screening: In individuals with symptoms suggestive of terminal ileitis, a thorough diagnostic workup is essential to differentiate etiologies.
• Tertiary:
  • Preventing Complications: Adherence to medication regimens, regular follow-up, endoscopic surveillance (for CD to detect dysplastic changes), nutritional support, and surgical intervention when indicated.
  • Smoking Cessation: Crucial for preventing disease flares and complications in CD.
  • Vaccinations: Ensure up-to-date vaccinations, especially for patients on immunosuppressive therapy (e.g., pneumococcal, influenza, hepatitis B, HPV, zoster if appropriate).

Special Populations

• Pediatric:
  • Diagnosis: Crohn's disease often presents with growth failure, delayed puberty, and perianal disease, sometimes preceding typical GI symptoms. Diagnostic workup is similar but with careful consideration of radiation exposure for imaging (prefer MRE over CTE, limit fluoroscopy).
  • Management: Focus on achieving mucosal healing and maintaining growth and development. Nutritional support (enteral nutrition often used as primary induction therapy for mild-to-moderate CD) is crucial. Biologics are increasingly used earlier in pediatric CD due to concerns about long-term steroid exposure.
  • Medication Dosing: Requires weight-based dosing and careful monitoring for side effects.
• Geriatric:
  • Diagnosis: Atypical presentations, overlap with other age-related conditions, and comorbidities can delay diagnosis. NSAID-induced enteropathy and ischemic ileitis are more common. Diverticulitis of the ileum is also more prevalent.
  • Management: Increased risk of medication side effects and drug-drug interactions due to polypharmacy and altered metabolism. More cautious use of corticosteroids. Higher risk of surgical complications.
  • Comorbidities: Careful consideration of cardiovascular disease, diabetes, and bone health.
• Pregnancy:
  • Diagnosis: Avoid radiation-emitting imaging (prefer MRE or ultrasound). Endoscopy can be performed safely.
  • Management: Goal is to maintain remission before and during pregnancy to prevent adverse outcomes (preterm birth, low birth weight). Most IBD medications (aminosalicylates, thiopurines, most biologics like infliximab, adalimumab, vedolizumab) are generally considered safe throughout pregnancy, though specific guidance should be sought. Methotrexate and thalidomide are contraindicated. Corticosteroids should be used cautiously.
  • Monitoring: Close collaboration between gastroenterologist, obstetrician, and maternal-fetal medicine specialist.
• Comorbidities:
  • Diabetes: Careful monitoring of blood glucose, especially with corticosteroid use.
  • Cardiovascular Disease: Increased risk of thromboembolic events in active IBD. Biologics may carry cardiovascular risks (e.g., anti-TNF agents and heart failure).
  • Renal Impairment: Adjust medication dosages, avoid nephrotoxic agents.
  • Immunosuppression: Increased risk of opportunistic infections. Careful screening for TB and other infections before starting immunosuppressive therapies.

Clinical Pearls

• Diagnostic:
  • Terminal ileitis is a symptom, not a diagnosis: Always pursue the underlying etiology.
  • "Appendicitis-like" presentation: Yersinia enterocolitica and early Crohn's disease can mimic acute appendicitis. Consider terminal ileitis in patients with RLQ pain where appendicitis is ruled out or atypical.
  • Fecal Calprotectin as a gatekeeper: A normal fecal calprotectin level (e.g., <50 µg/g) makes active IBD highly unlikely and can help avoid unnecessary invasive procedures like colonoscopy.
  • Biopsies are crucial: Always obtain biopsies from the terminal ileum during ileocolonoscopy, even if the mucosa appears normal, to rule out microscopic inflammation or specific infections.
  • Consider TB in endemic areas: If in doubt, treat for TB first, especially before starting immunosuppressants for suspected Crohn's, as immunosuppression can worsen TB.
• Treatment:
  • Smoking cessation is non-negotiable for Crohn's: It's the most impactful modifiable factor in disease course.
  • Nutrition matters: Address nutritional deficiencies proactively in patients with terminal ileitis, especially B12, iron, and vitamin D.
  • Early and aggressive therapy for Crohn's: "Treat-to-target" strategies aiming for mucosal healing improve long-term outcomes and reduce complications.
  • Beware of NSAIDs: Counsel all patients with IBD or history of terminal ileitis to avoid NSAIDs.
• Pitfalls:
  • Misdiagnosing Crohn's as infectious: Leading to delayed appropriate treatment and potential use of steroids without addressing infection.
  • Failure to consider TB: Especially in patients from endemic areas or who are immunocompromised. Missing TB can have catastrophic consequences if potent immunosuppressants (e.g., anti-TNF) are started.
  • Inadequate workup before capsule endoscopy: Not ruling out strictures with cross-sectional imaging can lead to capsule retention.
  • Over-reliance on steroids: Chronic steroid use leads to significant side effects (osteoporosis, diabetes, infections). Always aim to transition to steroid-sparing agents.
  • Ignoring extra-intestinal symptoms: These can be clues to an underlying systemic disease like Crohn's or Behcet's.

Recent Updates

• Guidelines: The American College of Gastroenterology (ACG) and European Crohn's and Colitis Organisation (ECCO) regularly update guidelines for the management of Crohn's disease, emphasizing treat-to-target strategies and early use of biologics in moderate-to-severe disease.
• Evidence:
  • New Biologics and Small Molecules: Recent approvals include ustekinumab (anti-IL12/23), vedolizumab (anti-integrin), and upadacitinib (JAK inhibitor), expanding therapeutic options for Crohn's disease, particularly for those failing anti-TNF therapy.
  • Role of Therapeutic Drug Monitoring (TDM): Growing evidence supports proactive TDM for anti-TNF agents to optimize drug levels, reduce immunogenicity, and improve outcomes.
  • Microbiome Research: Ongoing studies explore the role of fecal microbiota transplantation (FMT) and specific dietary interventions in modulating the gut microbiome for IBD, though not yet standard practice for Crohn's.
  • Non-invasive Monitoring: Continued validation of fecal calprotectin and serum CRP as reliable non-invasive markers for disease activity and response to therapy, helping to guide treatment decisions.
• Controversies:
  • Timing of Biologic Initiation: "Step-up" vs. "Top-down" approach in CD management. While treat-to-target supports early aggressive therapy, the optimal timing for all patients remains debated, balancing efficacy with risks.
  • Role of Diet in IBD: While certain diets (e.g., specific carbohydrate diet, FODMAP) can alleviate symptoms, their role in inducing or maintaining remission for inflammatory purposes is still under active investigation and not universally endorsed as primary therapy.
  • Surgical vs. Medical Management of Strictures: When to intervene surgically versus attempting endoscopic dilation for fibrotic strictures, especially in asymptomatic or mildly symptomatic patients.

Key References

• Guidelines:
  • ACG Clinical Guideline: Management of Crohn's Disease in Adults (e.g., Singh S et al., Am J Gastroenterol 2021;116:1120-1147).
  • ECCO Guidelines on Therapeutics in Crohn's Disease (e.g., Raine T et al., J Crohns Colitis 2022;16(suppl_2):S217-S232).
  • World Gastroenterology Organisation (WGO) Global Guidelines (e.g., IBD, Tuberculosis).
• Studies:
  • GEMINI Studies (Vedolizumab): Landmark trials establishing vedolizumab's efficacy in CD.
  • UNITI & IM-UNITI Studies (Ustekinumab): Key trials demonstrating ustekinumab's effectiveness in CD.
  • CELEST & U-ENDURE (Upadacitinib): Pivotal trials for JAK inhibitor in CD.
• Reviews:
  • Comprehensive reviews in major gastroenterology journals (e.g., Gastroenterology, Gut, Clinical Gastroenterology and Hepatology) on Crohn's disease pathophysiology, diagnosis, and management.
  • Reviews on specific infectious causes of terminal ileitis (e.g., Yersinia, Intestinal TB) from infectious disease literature.